Terry J. Smith, M.D.
Publications

• Hwang CJ, Khadavi NM, Papageorgiou K, Said J, Chong K, Lee D, Smith TJ, Goldberg RA, Douglas RS. Histopathology of brow fat in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg 2011 [in press] Nov 11. [Epub ahead of print]
• Tsui S, Fernando R, Chen B, Smith TJ. Divergent Sp1 levels may underlie differential expression of UDP glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves' disease. J Biol Chem 2011;286;24487-99.
• Smith TJ, Douglas RS, Nielsen HL. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol 2011;74:1-8
• Smith TJ, Douglas RS. Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy? Nat Rev Endocrinol 2011;7:505-6.
• Smith TJ, Padovani-Claudio DA, Lu Y, Raychaudhuri N, Fernando R, Atkins S, Gillespie EF, Gianoukakis AG, Miller BS, Gauger PG, Doherty GM, Douglas RS. Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in graves' disease. J Clin Endocrinol Metab 2011;96:3827-37. Epub 2011 Sep 28.
• Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. J Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. Endocrinol 2011;210:369-77. Epub 2011 Jun 29.
• Raychaudhuri N, Douglas RS, Smith TJ. PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One 2010;5:e15296.
• Hegedüs L, Smith TJ, Douglas RS, Nielsen CH. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol. 2011;74:1-8.
• Smith TJ. Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. Clin Exp Immunol 2010;162:24-31. Epub 2010 Aug 19. Review.
• Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010;62:199-236. Epub 2010 Apr 14. Review.
• Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest 2010;33:414-21.
• Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol 2010;55:215-226.
• Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ. Increased generation of fibrocytes in thyroid–associated ophthalmopathy. J Clin Endocrinol Metab 2010;95:430–8.
• Warstat K, Hoberg M, Rudert M, Tsui S, Pap T, Angres B, Essl M, Smith TJ, Cruikshank WW, Klein G, Gay S, Aicher WK. Transforming growth factor beta1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:270-5.
• Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, Goldberg RA, Darwin CH, Smith TJ, Douglas RS. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010;117:133-9.e2. Epub 2009 Oct 8.
• Douglas RS, Tsirbas A, Gordon M, Lee D, Khadavi N, Garneau HC, Goldberg RA, Cahill K, Dolman PJ, Elner V, Feldon S, Lucarelli M, Uddin J, Kazim M, Smith TJ, Khanna D; International Thyroid Eye Disease Society. Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Arch Ophthalmol 2009;127:1155-60.
• Douglas RS, Brix TH, Hwang CJ, Hegedüs L, Smith TJ. Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors. J Clin Endocrinol Metab 2009;94:1797-802. Epub 2009 Feb 24.
• Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ. Increased generation of fibrocytes in thyroid–associated ophthalmopathy. J Clin Endocrinol Metab 2010;95:430–438.
• Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ, Douglas RS. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 2009;50:2262-8. Epub 2008 Dec 30.

• Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, Kamat S, Smith TJ. B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: Implications for disease pathogenesis. J Immunol 2008;181:5768-74.
• Tsui S, Naik N, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. Evidence for an association between thyroid stimulating hormone and insulin-like growth factor 1 receptors: A tale of two antigens implicated in Graves’ disease. J Immunol 2008;181:4397-405.
• Smith TJ, Tsai CC, Shih M-J, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 2008;18:983-8.
• Naik V, Khadavi N, Naik MN, Hwang C, Goldberg RA, Tsirbas A, Smith TJ, Douglas RS. Biologic therapeutics in thyroid-associated ophthalmopathy: Translating disease mechanism into therapy. Thyroid 2008;18:967971.
• Smith TJ, Douglas RS. Pathophysiology of Graves’ Orbitopathy. In: D. Albert, J. Miller, D. Azar, B. Blodi, eds. Albert and Jakobiec’s Principles and Practice of Ophthalmology, 3rd ed.  Philadelphia:Saunders-Elsevier, 2008:2913-26.
• Han R, Chen B, Smith TJ. Janus kinase-2 dampens the induction by IL-1b of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts: Evidence for divergent influence on the PGE2 biosynthetic pathway. J Immunol2007;179:7147-56.
• Smith TJ. Editorial: Is a common therapy for autoimmune disease possible? Future Rheumatol2007;2:333-335.
• Smith TJ. Editorial: B cell depletion in Graves’ disease: The right answer to the wrong question? J Clin Endocrinol Metab 2007;92:1620-22.
• Douglas RS, Gianoukakis AG, Goldberg RA, Kamat S, Smith TJ. Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes.  Clin Exp Immunol 2007;148:64-71.
• Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 2007;178:3281-87.
• Chen B, Tsui S, Boeglin WE, Douglas RS, Brash AR, Smith TJ. IL-4 induces 15‑lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves’ disease: Evidence for anatomic site-selective action of TH2 cytokines. J Biol Chem 2006;281:18296-306.
• Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ. IgG from patients with Graves’ disease induces IL-16 and RANTES expression in cultured human thyrocytes: A putative mechanism for T cell infiltration of the thyroid in autoimmune disease. Endocrinology 2006;147:1941-49.
• Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases.  Clin Exp Immunol 2005;141:388-97.
• Chen B, Tsui S, Smith TJ. IL-1b induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotype attribute relevant to thyroid-associated ophthalmopathy. J Immunol2005;175:1310-19.
• Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest 2004;27:246-53.